Trimedyne's Chairman Speaks to the Investment Community on WallSt.Net.

IRVINE, Calif. -- Trimedyne Inc. (OTCBB:TMED) today announced its chairman, Marvin P. Loeb, described the company's products, medical applications and financial results in an audio interview on WallSt.Net.

Trimedyne recently reported its seventh consecutive quarterly profit. It manufactures Holmium Lasers and Optical Fibers for fragmenting stones in the kidney, ureter or bladder, and Laser Needles for use in new, outpatient procedures to treat herniated or ruptured discs in the spine.

"In our disc procedures, the patient's back pain usually disappears during or shortly after the approximate 20 to 40 minute procedure, and the patient typically walks out with only a band-aid on the puncture, no stitches, and is back to light activities in a few days. Surgery to treat these conditions generally requires a two-to-seven day hospital stay, a lengthy, recuperation period and a long absence from work," Loeb said.

"An estimated 10 million people in the United States suffer from back pain, most often from a damaged or diseased spinal disc," Loeb added.

To hear the entire interview, visit www.wallst.net, click on Audio Search and enter the TMED symbol. The audio interview will be available for a month or longer. For more information on Trimedyne, visit www.trimedyne.com.

www.wallst.net is owned and operated by Digital Wall Street Inc., a multimedia provider of original, insightful commentary and news from North America's leading companies. Giving a direct link to the management of today's fastest-growing companies through executive interviews and sector seminars, www.wallst.net provides a free service to consumers, and a paid, premium monthly subscription to its members.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act:

Statements in this news release and the audio interview may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the company's most recent report on Form 10-KSB and subsequently filed SEC reports. There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized or any forward-looking statements will prove accurate, as actual results and future events could differ materially from those presently anticipated.